Table 3.

Patient characteristics at initial progression

	Standard-dose Chemotherapy	Myeloablative Chemotherapy
Numbers of patients	56	27
Characteristics			P-value
Median age in years (range)	12.0 (0.4–22.1)	10.3 (0.4–21.1)	.35
Interval from diagnosis to progression in months (range)	9.7 (0.7–65.1)	6.8 (1.1–65.2)	.77
Irradiation/re-irradiation on progression	9 (16%)	*1 (4%)	0.16
Standard-dose chemotherapy	56 (100%)	*2 (8%)	<0.0001
Surgical debulking of tumor			.003
Debulked**	6 (11%)	11 (41%)
Non-debulked***	49	16

^*Prior to undergoing myeloablative chemotherapy;

^**Extent of resection was not available for one patient;

^***<3 cm tumor diameter for the myeloablative and gross total resection or at least 90% (≥90%) resection for the chemo control group.